As a new foreign trade service provider driven by both technology commercialization and foreign trade services, HiSiaddi has established a "1+2+3+4=1" service system and can supply original factory goods of acetyl L-carnitine hydrochloride from multiple well-known brands. As a tech-driven foreign trade service provider, HiSiaddi has conducted multiple rounds of factory inspections of acetyl L-carnitine hydrochloride manufacturers with years of market experience, possessing objective and in-depth understanding of different brands. Therefore, we regularly analyze various manufacturers of acetyl L-carnitine hydrochloride for clients to help them select matching products. Below is a brand selection case.
Please contact HiSiaddi customer service if you require more comparative analysis of brands and models.
The purchasing party is CERAMED Pharmaceutical Group based in Hamburg, Germany. With 28 years of deep engagement in R&D and production of prescription-grade cerebral nerve repair preparations, medical oral nutrient solutions and high-end sports nutrition soft capsules across Western Europe, its products are stocked in public pharmacy chains across Germany, EU clinical rehabilitation institutions and high-end organic dietary supplement supermarkets. Raw material access standards are extremely strict, complying with EP, USP Pharmacopoeia, FDA DMF filing, EFSA safety assessment, dual KOSHER/HALAL religious certifications and TSE/BSE animal-free statements. Its three core terminal products are cerebral nerve repair prescription drugs, high-purity oral drops and enteric soft capsules, with a stable annual purchase volume of 27 tons of acetyl L-carnitine hydrochloride, exclusively adopting high-end refined enzymatic pharmaceutical-grade raw materials instead of ordinary food-grade or low-cost industrial-grade raw materials. It is a typical mid-to-high-end European raw material purchaser, fundamentally different from intermediaries purchasing large volumes of low-priced generic goods in China.
The client had long imported acetyl L-carnitine hydrochloride from established Swiss pharmaceutical manufacturers before launching a localized alternative procurement plan for Chinese raw materials in 2025 due to shrinking local EU API production capacity, rising raw material prices and extended delivery cycles. During initial independent contact with five major domestic manufacturers (Chengda Pharmaceutical, Hubei Chuwei, Zhejiang Xianju, Ningxia Kunzheng, Jiangsu Pulai) for inquiry and sample delivery, the client fell into a brand selection dilemma: sales personnel of all five manufacturers only focused on promoting their own product advantages, avoiding objective elaboration of competing brands’ product characteristics, applicable formulation scenarios, model strengths and weaknesses. Lacking information reserves on China’s raw material market, the client’s R&D and procurement team could not distinguish differences in powder physical properties, impurity indicators and applicable dosage forms among various models of different brands. The 7 batches of samples sent by five manufacturers exhibited uneven physicochemical parameters, separately adapted to tableting, oral liquid and powder terminal formulations. The client failed to screen raw material models matching its dual formulations of cerebral nerve drops and enteric tablets after 45 days of work, delaying new product launch progress. The client then fully entrusted HiSiaddi to conduct full-process services covering in-depth research on mainstream domestic brands, horizontal parameter comparison and precise model selection.
Mandatory terminal product selection requirements of the client: simultaneous matching of two production lines (500mg enteric tablets and 15% high-concentration acidic oral drops). Raw materials must simultaneously satisfy: dry basis content ≥99.3%, single unknown impurity ≤0.05%, total impurities ≤0.14%; powder angle of repose 28°~30° compatible with high-speed tableting and complete dissolution at low temperature; enzymatic conversion production process with complete EU market access certifications, and delivery of 27 tons of annual orders split into multiple batches.
1. One-sided information from manufacturers’ self-promotion: Sales teams of Chengda, Chuwei, Xianju, Kunzheng and Pulai all prioritize promoting their flagship models, only explaining their own product strengths — Chengda highlights mass production cost performance, Chuwei emphasizes ultra-fine powder flowability, Xianju stresses pharmacopoeia compliance filing, Kunzheng focuses on feed and general food bulk raw materials, and Pulai specializes in small-batch customized orders. None voluntarily explain strengths and weaknesses of competing brands, preventing the client from horizontal benchmarking of pros and cons.
2. Client unfamiliar with domestic model classification rules: Domestic manufacturers divide products into three major grades (pharmaceutical EP grade, high-purity food grade, general mass production grade) under the same brand. All appear as white crystalline powder with indistinguishable indicator differences by naked eye. Adopting European raw material classification logic, the German client fails to understand domestic product naming rules for grades, unable to match multiple received samples with its own formulation demands.
3. Widely differentiated sample indicators leading to high cost of blind trial production: Among 7 samples from five manufacturers, 3 batches of general food-grade raw materials have excessive impurities suitable only for low-cost health products, unable to be used in prescription drug drops; 2 ultra-fine powder models deliver excellent water solubility yet insufficient powder flowability, causing severe sticking during tableting; the remaining 2 pharmaceutical-grade models have qualified powder properties yet high minimum order quantities inconsistent with the client’s small-batch phased stocking plan. If the client conducts trial production for each model one by one, estimated losses of auxiliary materials and production line debugging will exceed 52,000 EUR.
HiSiaddi set up a special team of raw material technical specialists, EU compliance specialists and on-site factory inspection specialists to conduct on-site verification of production lines, qualifications and in-production models of the five major manufacturers one by one, sorting out physical parameters, applicable scenarios, strengths and weaknesses of all mainstream products under each brand, and compiling a bilingual Chinese-English benchmark selection report:
Three mainstream available models: ① CD-EP01 (Pharmaceutical Pharmacopoeia Grade): Content 99.3%~99.5%, total impurities ≤0.13%, enzymatic process, conventional particle size powder, suitable for mass tableting production. Strengths: Large annual production capacity, stable delivery, complete DMF filings; Weaknesses: Conventional grade powder has relatively coarse particles, prone to trace precipitation in high-concentration liquid formulations, unsuitable for high-concentration drops. ② CD-FOOD02 (High-Purity Food Grade): Content 99.0%, total impurities ≤0.22%, high cost performance, suitable for general health product powders, failing to meet prescription drug impurity control standards. ③ CD-CUSTOM (Custom Modified Grade): Adjustable powder properties with minimum order quantity of 5 tons per batch, suitable for large-volume customized orders. Summary of brand strengths: Top-tier domestic mass production capacity with stable supply chains; Weaknesses: Poor liquid formulation compatibility of general pharmaceutical grade, high cost for small-batch customization.
Three mainstream available models: ① CW-PH01 (Ultra-Fine Pharmaceutical Grade): Content ≥99.4%, total impurities ≤0.12%, air-flow crushed for full passing through 100-mesh sieve with angle of repose 28.5%, completely soluble without precipitation in low-temperature acidic aqueous solutions, perfectly matching high-concentration oral liquids. Strengths: Industry-leading powder modification technology, self-developed three-stage chromatographic impurity removal process; Weaknesses: Limited conventional mass production capacity with slight price markup for large-volume continuous supply. ② CW-FD02 (General Food Grade): Conventional crystalline powder suitable for solid health product tableting with average water solubility. ③ CW-SPE03 (Special Medical Custom Grade): Ultra-low impurity specification exclusively supplied to European and American special medical enterprises with minimum order quantity of 3 tons. Summary of brand strengths: Outstanding compatibility with liquid formulations and excellent impurity control; Weaknesses: Slightly longer delivery cycle for large-volume centralized procurement.
Two mainstream available models: ① XJ-EP Pharmaceutical Grade: Content 99.35%, total impurities ≤0.135%, full-process pharmaceutical GMP control with complete EU market access certifications, balanced powder flowability compatible with both tablets and oral liquids. Strengths: Internal control standards higher than national standards, perfect drug administration traceability system; Weaknesses: High factory quotation with unit price markup for small and medium-batch procurement. ② XJ-F General Grade: Exclusively supplied to domestic health product market without supporting export compliance documents. Summary of brand strengths: Most complete compliance documents and stable quality consistency; Weaknesses: High procurement cost.
Two mainstream available models: KB-F1 Food Bulk Grade and KB-S Feed Grade. Both products have total impurities ranging from 0.28% to 0.35%, positioned as low-cost bulk goods only suitable for low-end health products and feed additives, without EP pharmacopoeia grades, failing to meet the client’s prescription drug access thresholds.
Two mainstream available models: PL-EP Small-Batch Pharmaceutical Custom Grade and PL-F General Food Grade. PL-EP has impurities ≤0.14%, flexible order splitting with minimum order quantity as low as 1.8 tons and adjustable powder properties on demand. Strengths: Flexible production scheduling for small batches with agile sample modification; Weaknesses: Limited annual production scale, facing heavy delivery pressure for annual orders exceeding 30 tons.
Synthesizing the client’s three core conditions (dual production lines for tablets and high-concentration drops, phased delivery of 27-ton annual orders, strict EU compliance), HiSiaddi eliminated Ningxia Kunzheng (substandard product grade) from the five brands and conducted horizontal screening of the remaining four manufacturers, finally confirming two mid-to-high-end brands (Hubei Chuwei and Zhejiang Xianju) with three segmented models in total, splitting the annual procurement order by specification:
1. CW-PH01 Ultra-Fine Pharmaceutical Grade: Exclusively supplied to the client’s 15% acidic oral drop production line with annual procurement of 11 tons split into 6 batches. Relying on its ultra-fine powder, complete low-temperature solubility and ultra-low impurity advantages, it completely resolves precipitation risks during liquid storage.
2. CW-SPE03 Special Medical Custom Grade: Reserved as an upgraded alternative model with a standby annual alternative order of 3 tons for formulation trial research of new infant drop products in the future.
XJ-EP Pharmacopoeia Pharmaceutical Grade: Exclusively supplied to the client’s 500mg enteric tablet production line with fixed annual procurement of 13 tons split into 5 batches scheduled monthly. Relying on Xianju’s complete GMP control and balanced powder physical properties, it resolves sticking and tablet weight fluctuation issues during automated high-speed tableting, with full DMF and EU certifications seamlessly matching German customs and drug administration verification requirements.
1. Elimination of Chengda Pharmaceutical: Poor compatibility of general pharmaceutical grade with liquid formulations and high minimum order quantity for customized grades, inconsistent with the client’s small-batch phased stocking model;
2. Elimination of Jiangsu Pulai: Advantages in small-batch supply only suit trial sample production, while the total annual order volume of 27 tons exceeds the stable mass production capacity of Pulai for full-year continuous supply;
3. Complementary advantages of Chuwei + Xianju combination: Chuwei specializes in raw materials for liquid dosage forms while Xianju excels at tablet raw materials. The two core models separately match the client’s two main production lines, with a reserved alternative special medical model for future new product R&D, balancing quality, delivery cycle and compliance requirements simultaneously.
HiSiaddi coordinated delivery of 500g full-item test samples of selected models from both manufacturers, with SGS conducting full-item testing in accordance with dual EP and USP standards, and samples simultaneously sent to the client’s R&D laboratory in Germany for formulation pilot testing:
1. CW-PH01 applied to drop formulations: No delamination or flocculent precipitation after 90 days of storage at 5°C, with all physicochemical indicators compliant;
2. XJ-EP applied to enteric tablet formulations: Angle of repose and flowability compatible with high-speed tablet presses, with RSD of tablet weight stably controlled within 2.2% and no sticking failures;
3. CW-SPE03 special medical samples retained in the client’s R&D warehouse for pre-experiments of new product formulations.
The client issued a formal qualification confirmation letter for the three models and officially signed an annual 27-ton procurement contract. HiSiaddi coordinated batch-by-batch shipment, supporting bilingual Chinese-English COA, certificate of origin, animal-free statements and complete EU compliance documents for each batch. The first batch of 4.2 tons of raw materials was shipped from Shanghai Port to Hamburg Port, Germany, achieving one-time smooth customs clearance and incoming inspection.
Compared with original Swiss imported raw materials, the overall procurement cost decreased by 23.6%, and ocean delivery cycle was shortened from 68 days to 33 days.
1. CERAMED Group of Germany completely terminated import channels from Swiss manufacturers, with 100% of its annual acetyl L-carnitine hydrochloride demand permanently sourced from two core models coordinated by HiSiaddi (Chuwei and Xianju). In the following year, it added demand for high-purity raw materials specially for new cerebral nerve drugs, with an additional annual procurement order of 9 tons;
2. The client entrusted HiSiaddi as its exclusive raw material selection service provider in China, delegating all brand screening and procurement coordination for high-end APIs such as L-carnitine series and GABA to HiSiaddi. Relying on the results of this brand selection project, HiSiaddi assisted Chuwei and Xianju in perfecting standardized specifications for EU special medical raw materials, successfully developing two equivalent high-end pharmaceutical clients in Austria and Switzerland.
Major domestic manufacturers of acetyl L-carnitine hydrochloride each focus on specialized tracks: some specialize in mass production of tablet raw materials, some excel at ultra-fine powder for liquids, and others target bulk general food raw materials. However, driven by self-interest in sales, all manufacturers generally only promote their own products and avoid objective elaboration of competing brands. Equipped with strict formulation standards for prescription drugs and special medical products, European and American mid-to-high-end pharmaceutical enterprises lack information on China’s raw material grading and segmented characteristics of various brand products. Independent docking with manufacturers easily leads to wrong model selection, failed sample trials and delayed projects.
Breaking the traditional foreign trade model of one-sided product promotion, HiSiaddi acts as a neutral third party to objectively disassemble strengths and weaknesses of mainstream domestic brands, applicable dosage forms and cost characteristics of each model horizontally, matching products precisely according to the client’s terminal formulations. It not only helps overseas mid-to-high-end clients avoid selection pitfalls and save trial sample loss costs, but also assists high-quality domestic mid-to-high-end API manufacturers to precisely access high-value EU pharmaceutical raw material supply chains and escape low-end price competition, achieving long-term win-win results for both supply and demand sides.
Please contact HiSiaddi customer service if you require more comparative analysis of brands and models.
+86-13120989737 
info@hisiaddi.com 
English
